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Abstract 
We report the case of a 38-year-old patient who was diagnosed with a cerebellar well-
differentiated neuroendocrine tumor (WDNET) in 2009. At first glance, we believed that it 
was a metastasis from an unrecognized WDNET arising outside the cerebellum. However, 
despite a prolonged follow-up of 6 years, an extracranial WDNET has never been found. Dur-
ing this time, the tumor recurred locally twice, and the patient was treated with surgery and 
radiotherapy. At the moment, he enjoys good general conditions and his tumor is under 
control. Due to the histopathological characteristics and clinical behavior of the tumor, we 
believe that this is the first report to date of a primary cerebellar WDNET. 
 © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Primary well-differentiated neuroendocrine tumors (WDNETs) arising in the intracra-
nial portion of the central nervous system (CNS) are occasional findings. To date, less than 
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10 cases of CNS WDNETs have been reported, 3 of which originated from cerebral hemi-
spheres or the skull base and another 3 were paragangliomas [1–6].  
On the other hand, the CNS more frequently represents a metastatic site for primary 
poorly differentiated NET arising elsewhere, most often in the lung (small-cell lung cancer) 
[7, 8]. In such cases, other secondary lesions, such as liver, lung and lymph nodes metastases, 
are often detected synchronously or metachronously with CNS localizations.  
Patients with WDNET and brain metastases are rare; typically they have a poor progno-
sis, with one study reporting a median survival time of 10.0 months after diagnosis of brain 
metastases [7]. Overall, brain metastases occur in 1.5–6% of all WDNETs, and their detection 
is usually preceded by the documentation of the primary, extracranial tumor [7, 8].  
Case Report 
In August 2009, a 38-year-old man referred to the hospital emergency department after 
a 2-month history of vertigos. Anamnesis and physical examination, including neurological 
evaluation, were not suggestive of any specific disease. Magnetic resonance (MR) imaging of 
the brain was performed which identified a large, heterogeneous contrast-enhancing lesion 
in the left cerebellar hemisphere, surrounded by significant edema (fig. 1, red arrows). Im-
ages were suspicious for a primary CNS neoplasm. Therefore, and given the potential risk for 
serious complications, immediate radical neurosurgery was performed, without previous 
systemic staging of the disease. Histology of the surgical specimen was compatible with a 
grade 2 (G2), WDNET localization with vaguely lobular architecture and sporadic small clus-
ters of foamy macrophages. Lobules of neoplastic cells were separated by a thin network of 
fibrous septa enriched in vessels with a few aggregates of mature lymphocytes within them. 
Neoplastic cells contained polygonal, eosinophilic cytoplasm and ovoid nuclei with irregular 
profiles, coarse chromatin and one or two eosinophilic nucleoli (fig. 2a, b). Several cells ex-
hibited finely vacuolar cytoplasm and a few rhabdoid cells were also present. Brisk mitotic 
activity was detected, with Ki67/MIB-1 staining positive in around 15–20% of tumor cells 
(fig. 2c). At immunohistochemistry, neoplastic cells diffusely expressed synaptophysin, 
chromogranin A (CgA) (fig. 2d) and neuron-specific enolase (NSE). EGFR was expressed on 
the cytoplasmic membrane of about 30% cells, while vimentin was detectable in the few 
rhabdoid cells. p53, EMA, cytokeratin CAM5.2, cytokeratin 7 and CD10 were expressed only 
in a few neoplastic cells, while staining was consistently negative for Neu-N, Oligo-1, myo-
genin, TTF-1, PSA, smooth muscle actin, Melan-A, Mart-1, S-100 protein, CD31, somatostatin 
receptor, cytokeratins AE1/AE3, GFAP and progesterone receptors.  
Then the patient came to our attention. Given the peculiarity of the case, we asked two 
other pathologists with proven experience in the field of NET to review the slides. The mor-
phological and immunohistochemical (IHC) analysis showed diffuse positive staining for the 
neuroendocrine markers such as synaptophysin, CgA and NSE, with a focal staining for cy-
tokeratins 7 and 8/18. Glioma markers (GFAP, S-100), calcitonin, pituitary (ACTH, FSH, GH, 
LH, PRL, TSH, alpha-SU), and gastroenteropancreatic and pulmonary NET hormones (sero-
tonin, gastrin, insulin, somatostatin, PP, glucagon/glycentin, CDX2, PDX1, TTF1) were in-
stead undetectable. A plausible differential diagnosis with Pineocytomas with mixed/in-
termediate differentiation (PPT) was proposed because PPT cells often assemble in lobular 
structures and stain positive for CgA, NSE and synaptophysin [9]. However, the absence of 
pineal localization in our case, and the cytological coarse chromatin aspect, was clearly dif-
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ferent from the typically stippled pattern observed in PPTs [9]. Both pathologists confirmed 
the diagnosis of G2 WDNET according to the criteria of the 2010 WHO classification [10]. 
Only one ectopic cerebellar localization of a presumptive, primary pineal tumor has 
been reported in the literature; in that case, the primary tumor consisted of an immature 
dysembryoma [11]. For these reasons, pathologists excluded the hypothesis of an ectopic 
PPT. 
Given that primary cerebellar WDNETs have never been described to date, the possibil-
ity of a brain metastasis from an elsewhere localized WDNET was considered reliable. How-
ever, extensive imaging studies, including computed tomography (CT), 68Ga PET and 18FDG-
PET, did not show any evidence of extracranial primary tumor. Despite this, we expected 
that a primary NET located outside the brain, or other organ metastases, would become evi-
dent over a prolonged follow-up, also since no systemic treatment was administered to in-
hibit the growth of potentially present extracerebral tumor cells. However, total-body radio-
logical studies including brain CT and MR imaging regularly performed every 6 months 
proved negative, and the patient remained asymptomatic and in good general conditions, 
without evidence of other extracerebral localizations of the disease. 
In October 2012, vertigos reappeared and a brain MRI examination documented one lo-
cal recurrence of the previously resected left hemisphere cerebellar lesion and the appear-
ance of a new small lesion in maximum diameter, located at the left cerebellopontine angle 
(fig. 3, red arrows). Extensive systemic staging including 68Ga PET was performed, but again 
no extracranial localizations were detected. Partial surgical resection of the cerebellopontine 
lesion was then performed, followed by stereotactic radiotherapy on residual disease (60 
Gy) and on left cerebellar hemisphere (50 Gy). Pathological and IHC examination of the re-
currence confirmed the primary diagnosis.  
In June 2014, another cerebellar recurrence was treated with radiotherapy (50 Gy). The 
patient also underwent total-spine MR imaging and cytological evaluation of cerebrospinal 
fluid, none of which showed any evidence of disease. At the last control in July 2015, minimal 
disease persistence at the cerebellopontine angle (13 × 6 × 9 mm) was documented by brain 
MRI, with the patient remaining substantially asymptomatic and involved in normal daily 
and working activities. Despite biannual systemic re-evaluations with total-body contrast-
enhanced CT and 68Ga PET, according to the clinical course of SNC primary tumors, extracra-
nial disease has never become evident over a total follow-up of 6 years.  
Discussion 
In 10–13% of metastatic WDNETs, the primary tumor cannot be identified at diagnosis 
and can even remain occult during the entire course of the disease, with the liver being the 
main site of metastatic spread in such cases [12]. This can be explained by three different 
hypotheses: (a) if clinical follow-up is long enough, the primary tumor eventually becomes 
detectable; (b) the primary lesion remains small or even spontaneously regresses due to 
poor vascularization or clearing by the immune system; (c) the primary tumor arises in the 
same organ that is erroneously considered the metastatic site (in most cases the liver) [13].  
The case described here unlikely represents a metastatic-to-the-cerebellum WDNET of 
unknown primary origin because of the following reasons. 
(1) The putative primary extracranial tumor has not been detected during a prolonged, 
6-year-long follow-up. This strongly contrasts with data in the literature, where detection of 
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brain metastases of elsewhere localized primary WDNETs has always been preceded by the 
detection of the primary neoplasm, most often at the lungs [7, 8]. 
(2) Tumor recurrences occurred in the same area of the brain as the first detected le-
sion, whereas lesions in sites that are preferential metastatic localizations of extracranial 
WDNETs, such as the liver and thoracic/abdominal lymph nodes, have never been found. 
(3) Although IHC markers of WDNETs are not absolutely specific of any anatomic origin, 
the lack of TTF1, CDX2 and PDX1 expression in the tumor makes it unlikely to originate from 
the lung, gut and pancreas [14], thus probably excluding the most frequent sites of NET 
origin. 
(4) The clinical indolent course of the patient, characterized by long-term survival, is 
typical of advanced WDNETs. 
(5) Although it cannot be definitively excluded that a small, primary extracranial NET 
has metastasized to the brain before becoming quiescent or even being cleared by the im-
mune system, it is hard to believe that the liver, lung and lymph nodes were completely 
spared, with the cerebellum instead being the only site of subsequent metastatic waves. 
(6) Plausible differential diagnoses, including PPT and cerebellar medulloblastoma 
(MB). 
We therefore conclude that this case represents the first pathological report of a prima-
ry cerebellar WDNET. Recurrences observed during patient follow-up represent, in our opin-
ion, locoregional relapses of the primary CNS tumor. This work aims, above all, to make 
aware pathologists and clinicians about the existence of primary WDNETs of the CNS. These 
tumors would definitively consist of very rare entities, neglected until now because errone-
ously considered metastatic localizations of elsewhere located primary neuroendocrine ne-
oplasms. They could originate from sparse cerebellar cells of the diffuse neuroendocrine 
system. 
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Fig. 1. a Coronal plane, nonenhanced T1-weighted MR scan. b Axial, FLARE sequence. c Coronal plane, T2-
weighted MR scan. d Sagittal plane, contrast-enhanced T1-weighted scan. 
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Fig. 2. Hematoxylin-eosin staining: ×10 magnification (a), ×20 magnification (b). c IHC for MIB1. d IHC for 
chromogranin A. 
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Fig. 3. a Axial, contrast-enhanced T1-weighted MR scan. b Coronal, contrast-enhanced T1 scan. c Sagittal 
plane, T1-weighted MR scan, no contrast. d Axial plane, FLAIR sequence. 
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